Dehydroepiandrosterone: A new treatment for vascular remodeling diseases including pulmonary arterial hypertension

Pharmacology and Therapeutics

Volumn 126, Issue 2, 2010, Pages 186-199

  Dumas de la Roque, Eric ^a,b   Savineau, Jean Pierre ^b,c   Bonnet, Sébastien ^d  

^a HÔPITAL PELLEGRIN   (France)

^b INSERM   (France)

^c UNIVERSITÉ DE BORDEAUX   (France)

^d LAVAL UNIVERSITY   (Canada)

Author keywords

DHEA; HIF 1 and NFAT; Mitochondria; PI3K; Pulmonary arterial hypertension; Smooth muscle cell

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; AMBRISENTAN; BOSENTAN; CALCIUM ACTIVATED POTASSIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; CYCLIC GMP; DILTIAZEM; ENDOTHELIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; ILOPROST; MONOCROTALINE; NIFEDIPINE; NITRIC OXIDE; PHOSPHATIDYLINOSITOL 3 KINASE; POTASSIUM CHANNEL KV1.5; PRASTERONE; PROSTACYCLIN; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SILDENAFIL; SITAXSENTAN; TRANSIENT RECEPTOR POTENTIAL CHANNEL; TREACLEER; UNCLASSIFIED DRUG; UNIPROST;

ADRENAL INSUFFICIENCY; APOPTOSIS; ARTERIAL WALL THICKNESS; CALCIUM TRANSPORT; CARDIOVASCULAR DISEASE; CLINICAL CLASSIFICATION; DEPRESSION; DISEASE MODEL; DRUG HALF LIFE; DRUG SELECTIVITY; DRUG TOLERABILITY; DUCTUS ARTERIOSUS OBLITERATION; ENDOTHELIAL DYSFUNCTION; HEART VENTRICLE HYPERTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOXIA; LUNG VASCULAR RESISTANCE; LUNG VASOCONSTRICTION; MITOCHONDRIAL MEMBRANE POTENTIAL; NONHUMAN; OPTIMAL DRUG DOSE; OSTEOPOROSIS; PATHOPHYSIOLOGY; POTASSIUM CURRENT; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; STEROID METABOLISM; STEROIDOGENESIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TRANSGENIC ANIMAL;

EID: 77951092239     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2010.02.003     Document Type: Review

References (230)

1. Abe K., Shimokawa H., Morikawa K., Uwatoku T., Oi K., Matsumoto Y., et al. Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circ Res 2004, 94:385-393.
2. Abrams D.I., Shade S.B., Couey P., McCune J.M., Lo J., Bacchetti P., et al. Dehydroepiandrosterone (DHEA) effects on HIV replication and host immunity: a randomized placebo-controlled study. AIDS Res Hum Retroviruses 2007, 23:77-85.
3. Agard C., Rolli-Derkinderen M., Dumas-de-La-Roque E., Rio M., Sagan C., Savineau J.P., et al. Protective role of the antidiabetic drug metformin against chronic experimental pulmonary hypertension. Br J Pharmacol 2009, 158:1285-1294.
4. Agnoletti G., Cornacchiari A., Panzali A.F., Ghielmi S., De Giuli F., Ferrari R. Effect of congestive heart failure on rate of atrial natriuretic factor release in response to stretch and isoprenaline. Cardiovasc Res 1990, 24:938-945.
5. Albert A.P., Large W.A. Store-operated Ca2+-permeable non-selective cation channels in smooth muscle cells. Cell Calcium 2003, 33:345-356.
6. Allolio B., Arlt W. DHEA treatment: myth or reality?. Trends Endocrinol Metab 2002, 13:288-294.
7. Archer S.L., Souil E., Dinh-Xuan A.T., Schremmer B., Mercier J.C., El Yaagoubi A., et al. Molecular identification of the role of voltage-gated K+channels, Kv1.5 and Kv2.1, in hypoxic pulmonary vasoconstriction and control of resting membrane potential in rat pulmonary artery myocytes. J Clin Invest 1998, 101:2319-2330.
8. Badesch D.B., Abman S.H., Ahearn G.S., Barst R.J., McCrory D.C., Simonneau G., et al. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004, 126:35S-62S.
9. Badesch D.B., Abman S.H., Simonneau G., Rubin L.J., McLaughlin V.V. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 2007, 131:1917-1928.
10. Bae Y.M., Park M.K., Lee S.H., Ho W.K., Earm Y.E. Contribution of Ca2+-activated K+channels and non-selective cation channels to membrane potential of pulmonary arterial smooth muscle cells of the rabbit. J Physiol 1999, 514(Pt 3):747-758.
11. Barrett-Connor E., Goodman-Gruen D. Dehydroepiandrosterone sulfate does not predict cardiovascular death in postmenopausal women. The Rancho Bernardo Study. Circulation 1995, 91:1757-1760.
12. Barrett-Connor E., Goodman-Gruen D. The epidemiology of DHEAS and cardiovascular disease. Ann N Y Acad Sci 1995, 774:259-270.
13. Barrett-Connor E., Khaw K.T. Absence of an inverse relation of dehydroepiandrosterone sulfate with cardiovascular mortality in postmenopausal women. N Engl J Med 1987, 317:711.
14. Barrett-Connor E., Khaw K.T., Yen S.S. A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease. N Engl J Med 1986, 315:1519-1524.
15. Barst R.J., Langleben D., Badesch D., Frost A., Lawrence E.C., Shapiro S., et al. Treatment of pulmonary arterial hypertension with the selective endothelin-a receptor antagonist sitaxsentan. J Am Coll Cardiol 2006, 47:2049-2056.
16. Barst R.J., Langleben D., Frost A., Horn E.M., Oudiz R., Shapiro S., et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004, 169:441-447.
17. Barst R.J., McGoon M., Torbicki A., Sitbon O., Krowka M.J., Olschewski H., et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004, 43:40S-47S.
18. Baulieu E.E. Androgens and aging men. Mol Cell Endocrinol 2002, 198:41-49.
19. Baulieu E.E., Corpechot C., Dray F., Emiliozzi R., Lebeau M.C., Mauvais Jarvis P., et al. An adrenal-secreted "androgen": dehydroisoandrosterone sulfate. Its metabolism and a tentative generalization on the metabolism of other steroid conjugates in man. Recent Prog Horm Res 1965, 21:411-500.
20. Belanger A., Candas B., Dupont A., Cusan L., Diamond P., Gomez J.L., et al. Changes in serum concentrations of conjugated and unconjugated steroids in 40- to 80-year-old men. J Clin Endocrinol Metab 1994, 79:1086-1090.
21. Bennett M.R. Apoptosis in the cardiovascular system. Heart 2002, 87:480-487.
22. Bernini G.P., Moretti A., Sgro M., Argenio G.F., Barlascini C.O., Cristofani R., et al. Influence of endogenous androgens on carotid wall in postmenopausal women. Menopause 2001, 8:43-50.
23. Berr C., Lafont S., Debuire B., Dartigues J.F., Baulieu E.E. Relationships of dehydroepiandrosterone sulfate in the elderly with functional, psychological, and mental status, and short-term mortality: a French community-based study. Proc Natl Acad Sci U S A 1996, 93:13410-13415.
24. Berridge M.J. The endoplasmic reticulum: a multifunctional signaling organelle. Cell Calcium 2002, 32:235-249.
25. Berridge M.J., Lipp P., Bootman M.D. The versatility and universality of calcium signalling. Nat Rev Mol Cell Biol 2000, 1:11-21.
26. Bonnet S., Archer S.L. Potassium channel diversity in the pulmonary arteries and pulmonary veins: Implications for regulation of the pulmonary vasculature in health and during pulmonary hypertension. Pharmacol Ther 2007, 115:56-69.
27. Bonnet S., Archer S.L., Allalunis-Turner J., Haromy A., Beaulieu C., Thompson R., et al. A mitochondria-K+channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 2007, 11:37-51.
28. Bonnet S., Belus A., Hyvelin J.M., Roux E., Marthan R., Savineau J.P. Effect of chronic hypoxia on agonist-induced tone and calcium signaling in rat pulmonary artery. Am J Physiol Lung Cell Mol Physiol 2001, 281:L193-201.
29. Bonnet S., Dubuis E., Vandier C., Martin S., Marthan R., Savineau J.P. Reversal of chronic hypoxia-induced alterations in pulmonary artery smooth muscle electromechanical coupling upon air breathing. Cardiovasc Res 2002, 53:1019-1028.
30. Bonnet S., Dumas-de-La-Roque E., Begueret H., Marthan R., Fayon M., Dos Santos P., et al. Dehydroepiandrosterone (DHEA) prevents and reverses chronic hypoxic pulmonary hypertension. Proc Natl Acad Sci U S A 2003, 100:9488-9493.
31. Bonnet S., Hyvelin J.M., Bonnet P., Marthan R., Savineau J.P. Chronic hypoxia-induced spontaneous and rhythmic contractions in the rat main pulmonary artery. Am J Physiol Lung Cell Mol Physiol 2001, 281:L183-192.
32. Bonnet S., Michelakis E.D., Porter C.J., Andrade-Navarro M.A., Thebaud B., Bonnet S., et al. An abnormal mitochondrial-hypoxia inducible factor-1alpha-Kv channel pathway disrupts oxygen sensing and triggers pulmonary arterial hypertension in fawn hooded rats: similarities to human pulmonary arterial hypertension. Circulation 2006, 113:2630-2641.
33. Bonnet S., Paulin R., Sutendra G., Dromparis P., Roy M., Nagendran J., et al. Dehydroepiandrosterone reverses systemic vascular remodeling through the inhibition of the Akt/GSK3-{beta}/NFAT axis. Circulation 2009, 20:1231-1240.
34. Bonnet S., Rochefort G., Sutendra G., Archer S.L., Haromy A., Webster L., et al. The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted. Proc Natl Acad Sci U S A 2007, 104:11418-11423.
35. Bonnet S., Savineau J.P., Barillot W., Dubuis E., Vandier C., Bonnet P. Role of Ca(2+)-sensitive K(+) channels in the remission phase of pulmonary hypertension in chronic obstructive pulmonary diseases. Cardiovasc Res 2003, 60:326-336.
36. Brevnova E.E., Platoshyn O., Zhang S., Yuan J.X. Overexpression of human KCNA5 increases IK V and enhances apoptosis. Am J Physiol Cell Physiol 2004, 287:C715-722.
37. Budts W., Pokreisz P., Nong Z., Van Pelt N., Gillijns H., Gerard R., et al. Aerosol gene transfer with inducible nitric oxide synthase reduces hypoxic pulmonary hypertension and pulmonary vascular remodeling in rats. Circulation 2000, 102:2880-2885.
38. Campbell B.C., Leslie P., Campbell K. Age-related patterns of DHEAS among Turkana males of northern Kenya. Aging Male 2007, 10:203-209.
39. Casson P.R., Andersen R.N., Herrod H.G., Stentz F.B., Straughn A.B., Abraham G.E., et al. Oral dehydroepiandrosterone in physiologic doses modulates immune function in postmenopausal women. Am J Obstet Gynecol 1993, 169:1536-1539.
40. Channick R.N., Simonneau G., Sitbon O., Robbins I.M., Frost A., Tapson V.F., et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001, 358:1119-1123.
41. Chen E.P., Bittner H.B., Tull F., Biswas S.S., Davis R.D., Van Trigt P. An adult canine model of chronic pulmonary hypertension for cardiopulmonary transplantation. J Heart Lung Transplant 1997, 16:538-547.
42. Clapp L.H., Gurney A.M. Modulation of calcium movements by nitroprusside in isolated vascular smooth muscle cells. Pflugers Arch 1991, 418:462-470.
43. Clapp L.H., Gurney A.M. ATP-sensitive K+channels regulate resting potential of pulmonary arterial smooth muscle cells. Am J Physiol 1992, 262:H916-920.
44. Contoreggi C.S., Blackman M.R., Andres R., Muller D.C., Lakatta E.G., Fleg J.L., et al. Plasma levels of estradiol, testosterone, and DHEAS do not predict risk of coronary artery disease in men. J Androl 1990, 11:460-470.
45. Cornfield D.N., Resnik E.R., Herron J.M., Abman S.H. Chronic intrauterine pulmonary hypertension decreases calcium-sensitive potassium channel mRNA expression. Am J Physiol Lung Cell Mol Physiol 2000, 279:L857-862.
46. Crabtree G.R., Olson E.N. NFAT signaling: choreographing the social lives of cells. Cell 2002, 109(Suppl):S67-79.
47. de Peretti E., Forest M.G. Pattern of plasma dehydroepiandrosterone sulfate levels in humans from birth to adulthood: evidence for testicular production. J Clin Endocrinol Metab 1978, 47:572-577.
48. Dessouroux A., Akwa Y., Baulieu E.E. DHEA decreases HIF-1alpha accumulation under hypoxia in human pulmonary artery cells: potential role in the treatment of pulmonary arterial hypertension. J Steroid Biochem Mol Biol 2008, 109:81-89.
49. Dinh-Xuan A.T., Higenbottam T.W., Clelland C.A., Pepke-Zaba J., Cremona G., Butt A.Y., et al. Impairment of endothelium-dependent pulmonary-artery relaxation in chronic obstructive lung disease. N Engl J Med 1991, 324:1539-1547.
50. Dipp M., Nye P.C., Evans A.M. Hypoxic release of calcium from the sarcoplasmic reticulum of pulmonary artery smooth muscle. Am J Physiol Lung Cell Mol Physiol 2001, 281:L318-325.
51. Dupuis J., Hoeper M.M. Endothelin receptor antagonists in pulmonary arterial hypertension. Eur Respir J 2008, 31:407-415.
52. Durmowicz A.G., Stenmark K.R. Mechanisms of structural remodeling in chronic pulmonary hypertension. Pediatr Rev 1999, 20:e91-e102.
53. Eddahibi S., Hanoun N., Lanfumey L., Lesch K.P., Raffestin B., Hamon M., et al. Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene. J Clin Invest 2000, 105:1555-1562.
54. Emery C.J., Bee D., Barer G.R. Mechanical properties and reactivity of vessels in isolated perfused lungs of chronically hypoxic rats. Clin Sci (Lond) 1981, 61:569-580.
55. Evgenov O.V., Kohane D.S., Bloch K.D., Stasch J.P., Volpato G.P., Bellas E., et al. Inhaled agonists of soluble guanylate cyclase induce selective pulmonary vasodilation. Am J Respir Crit Care Med 2007, 176:1138-1145.
56. Evgenov O.V., Pacher P., Schmidt P.M., Hasko G., Schmidt H.H., Stasch J.P. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov 2006, 5:755-768.
57. Fagan K.A., Fouty B.W., Tyler R.C., Morris K.G., Hepler L.K., Sato K., et al. The pulmonary circulation of homozygous or heterozygous eNOS-null mice is hyperresponsive to mild hypoxia. J Clin Invest 1999, 103:291-299.
58. Fagan K.A., Oka M., Bauer N.R., Gebb S.A., Ivy D.D., Morris K.G., et al. Attenuation of acute hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension in mice by inhibition of Rho-kinase. Am J Physiol Lung Cell Mol Physiol 2004, 287:L656-664.
59. Farrukh I.S., Peng W., Orlinska U., Hoidal J.R. Effect of dehydroepiandrosterone on hypoxic pulmonary vasoconstriction: a Ca(2+)-activated K(+)-channel opener. Am J Physiol 1998, 274:L186-195.
60. Flugel D., Gorlach A., Michiels C., Kietzmann T. Glycogen synthase kinase 3 phosphorylates hypoxia-inducible factor 1alpha and mediates its destabilization in a VHL-independent manner. Mol Cell Biol 2007, 27:3253-3265.
61. Furutama D., Fukui R., Amakawa M., Ohsawa N. Inhibition of migration and proliferation of vascular smooth muscle cells by dehydroepiandrosterone sulfate. Biochim Biophys Acta 1998, 1406:107-114.
62. Galie N., Ghofrani H.A., Torbicki A., Barst R.J., Rubin L.J., Badesch D., et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005, 353:2148-2157.
63. Galie N., Olschewski H., Oudiz R.J., Torres F., Frost A., Ghofrani H.A., et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008, 117:3010-3019.
64. Gayosso V., Montano L.F., Lopez-Marure R. DHEA-induced antiproliferative effect in MCF-7 cells is androgen- and estrogen receptor-independent. Cancer J 2006, 12:160-165.
65. Gelband C.H., Gelband H. Ca2+ release from intracellular stores is an initial step in hypoxic pulmonary vasoconstriction of rat pulmonary artery resistance vessels. Circulation 1997, 96:3647-3654.
66. Geraci M.W., Gao B., Shepherd D.C., Moore M.D., Westcott J.Y., Fagan K.A., et al. Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension. J Clin Invest 1999, 103:1509-1515.
67. Golden S.H., Maguire A., Ding J., Crouse J.R., Cauley J.A., Zacur H., et al. Endogenous postmenopausal hormones and carotid atherosclerosis: a case-control study of the atherosclerosis risk in communities cohort. Am J Epidemiol 2002, 155:437-445.
68. Golovina V.A., Platoshyn O., Bailey C.L., Wang J., Limsuwan A., Sweeney M., et al. Upregulated TRP and enhanced capacitative Ca(2+) entry in human pulmonary artery myocytes during proliferation. Am J Physiol Heart Circ Physiol 2001, 280:H746-755.
69. Guerard P., Rakotoniaina Z., Goirand F., Rochette L., Dumas M., Lirussi F., et al. The HMG-CoA reductase inhibitor, pravastatin, prevents the development of monocrotaline-induced pulmonary hypertension in the rat through reduction of endothelial cell apoptosis and overexpression of eNOS. Naunyn Schmiedebergs Arch Pharmacol 2006, 373:401-414.
70. Guibert C., Ducret T., Savineau J.P. Voltage-independent calcium influx in smooth muscle. Prog Biophys Mol Biol 2008, 98:10-23.
71. Guibert C., Marthan R., Savineau J.P. 5-HT induces an arachidonic acid-sensitive calcium influx in rat small intrapulmonary artery. Am J Physiol Lung Cell Mol Physiol 2004, 286:L1228-1236.
72. Guibert C., Marthan R., Savineau J.P. Modulation of ion channels in pulmonary arterial hypertension. Curr Pharm Des 2007, 13:2443-2455.
73. Guignabert C., Izikki M., Tu L.I., Li Z., Zadigue P., Barlier-Mur A.M., et al. Transgenic mice overexpressing the 5-hydroxytryptamine transporter gene in smooth muscle develop pulmonary hypertension. Circ Res 2006, 98:1323-1330.
74. Guignabert C., Raffestin B., Benferhat R., Raoul W., Zadigue P., Rideau D., et al. Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats. Circulation 2005, 111:2812-2819.
75. Guilluy C., Sauzeau V., Rolli-Derkinderen M., Guerin P., Sagan C., Pacaud P., et al. Inhibition of RhoA/Rho kinase pathway is involved in the beneficial effect of sildenafil on pulmonary hypertension. Br J Pharmacol 2005, 146:1010-1018.
76. Gupte S.A., Li K.X., Okada T., Sato K., Oka M. Inhibitors of pentose phosphate pathway cause vasodilation: involvement of voltage-gated potassium channels. J Pharmacol Exp Ther 2002, 301:299-305.
77. Gurney A.M., Osipenko O.N., MacMillan D., McFarlane K.M., Tate R.J., Kempsill F.E. Two-pore domain K channel, TASK-1, in pulmonary artery smooth muscle cells. Circ Res 2003, 93:957-964.
78. Haffner S.M., Moss S.E., Klein B.E., Klein R. Sex hormones and DHEA-SO4 in relation to ischemic heart disease mortality in diabetic subjects. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Diabetes Care 1996, 19:1045-1050.
79. Hampl V., Bibova J., Povysilova V., Herget J. Dehydroepiandrosterone sulphate reduces chronic hypoxic pulmonary hypertension in rats. Eur Respir J 2003, 21:862-865.
80. Hardingham G.E., Chawla S., Johnson C.M., Bading H. Distinct functions of nuclear and cytoplasmic calcium in the control of gene expression. Nature 1997, 385:260-265.
81. Hardziyenka M., Campian M.E., de Bruin-Bon H.A., Michel M.C., Tan H.L. Sequence of echocardiographic changes during development of right ventricular failure in rat. J Am Soc Echocardiogr 2006, 19:1272-1279.
82. Hautanen A., Manttari M., Manninen V., Tenkanen L., Huttunen J.K., Frick M.H., et al. Adrenal androgens and testosterone as coronary risk factors in the Helsinki Heart Study. Atherosclerosis 1994, 105:191-200.
83. Hayashi T., Esaki T., Muto E., Kano H., Asai Y., Thakur N.K., et al. Dehydroepiandrosterone retards atherosclerosis formation through its conversion to estrogen: the possible role of nitric oxide. Arterioscler Thromb Vasc Biol 2000, 20:782-792.
84. Herrington D.M. Dehydroepiandrosterone and coronary atherosclerosis. Ann N Y Acad Sci 1995, 774:271-280.
85. Hinson J.P., Khan M. Dehydroepiandrosterone sulphate (DHEAS) inhibits growth of human vascular endothelial cells. Endocr Res 2004, 30:667-671.
86. Hogg D.S., Davies A.R., McMurray G., Kozlowski R.Z. K(V)2.1 channels mediate hypoxic inhibition of I(KV) in native pulmonary arterial smooth muscle cells of the rat. Cardiovasc Res 2002, 55:349-360.
87. Homma N., Nagaoka T., Karoor V., Imamura M., Taraseviciene-Stewart L., Walker L.A., et al. Involvement of RhoA/Rho kinase signaling in protection against monocrotaline-induced pulmonary hypertension in pneumonectomized rats by dehydroepiandrosterone. Am J Physiol Lung Cell Mol Physiol 2008, 295:L71-78.
88. Hulme J.T., Coppock E.A., Felipe A., Martens J.R., Tamkun M.M. Oxygen sensitivity of cloned voltage-gated K(+) channels expressed in the pulmonary vasculature. Circ Res 1999, 85:489-497.
89. Humbert M., Sitbon O., Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004, 351:1425-1436.
90. Ishihara F., Hiramatsu K., Shigematsu S., Aizawa T., Niwa A., Takasu N., et al. Role of adrenal androgens in the development of arteriosclerosis as judged by pulse wave velocity and calcification of the aorta. Cardiology 1992, 80:332-338.
91. Janiak R., Wilson S.M., Montague S., Hume J.R. Heterogeneity of calcium stores and elementary release events in canine pulmonary arterial smooth muscle cells. Am J Physiol Cell Physiol 2001, 280:C22-33.
92. Jansson J.H., Nilsson T.K., Johnson O. von Willebrand factor, tissue plasminogen activator, and dehydroepiandrosterone sulphate predict cardiovascular death in a 10year follow up of survivors of acute myocardial infarction. Heart 1998, 80:334-337.
93. Jeffery T.K., Wanstall J.C. Pulmonary vascular remodeling: a target for therapeutic intervention in pulmonary hypertension. Pharmacol Ther 2001, 92:1-20.
94. Jernigan N.L., Walker B.R., Resta T.C. Chronic hypoxia augments protein kinase G-mediated Ca2+ desensitization in pulmonary vascular smooth muscle through inhibition of RhoA/Rho kinase signaling. Am J Physiol Lung Cell Mol Physiol 2004, 287:L1220-1229.
95. Jiang H., Li H., DiMario J.X. Control of slow myosin heavy chain 2 gene expression by glycogen synthase kinase activity in skeletal muscle fibers. Cell Tissue Res 2006, 323:489-494.
96. Jiang Y., Miyazaki T., Honda A., Hirayama T., Yoshida S., Tanaka N., et al. Apoptosis and inhibition of the phosphatidylinositol 3-kinase/Akt signaling pathway in the anti-proliferative actions of dehydroepiandrosterone. J Gastroenterol 2005, 40:490-497.
97. Keegan A., Morecroft I., Smillie D., Hicks M.N., MacLean M.R. Contribution of the 5-HT(1B) receptor to hypoxia-induced pulmonary hypertension: converging evidence using 5-HT(1B)-receptor knockout mice and the 5-HT(1B/1D)-receptor antagonist GR127935. Circ Res 2001, 89:1231-1239.
98. Kentera D., Susic D., Veljkovic V., Tucakovic G., Koko V. Pulmonary artery pressure in rats with hereditary platelet function defect. Respiration 1988, 54:110-114.
99. Khaw K.T., Tazuke S., Barrett-Connor E. Cigarette smoking and levels of adrenal androgens in postmenopausal women. N Engl J Med 1988, 318:1705-1709.
100. Kiechl S., Willeit J., Bonora E., Schwarz S., Xu Q. No association between dehydroepiandrosterone sulfate and development of atherosclerosis in a prospective population study (Bruneck Study). Arterioscler Thromb Vasc Biol 2000, 20:1094-1100.
101. Klinger J.R. The nitric oxide/cGMP signaling pathway in pulmonary hypertension. Clin Chest Med 2007, 28:143-167. ix.
102. Krick S., Platoshyn O., Sweeney M., Kim H., Yuan J.X. Activation of K+channels induces apoptosis in vascular smooth muscle cells. Am J Physiol Cell Physiol 2001, 280:C970-979.
103. Labrie F., Belanger A., Cusan L., Gomez J.L., Candas B. Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging. J Clin Endocrinol Metab 1997, 82:2396-2402.
104. Labrie F., Luu-The V., Belanger A., Lin S.X., Simard J., Pelletier G., et al. Is dehydroepiandrosterone a hormone?. J Endocrinol 2005, 187:169-196.
105. Labrie F., Luu-The V., Labrie C., Simard J. DHEA and its transformation into androgens and estrogens in peripheral target tissues: intracrinology. Front Neuroendocrinol 2001, 22:185-212.
106. LaCroix A.Z., Yano K., Reed D.M. Dehydroepiandrosterone sulfate, incidence of myocardial infarction, and extent of atherosclerosis in men. Circulation 1992, 86:1529-1535.
107. Lalich J.L., Johnson W.D., Raczniak T.J., Shumaker R.C. Fibrin thrombosis in monocrotaline pyrrole-induced cor pulmonale in rats. Arch Pathol Lab Med 1977, 101:69-73.
108. Landsberg J.W., Yuan J.X. Calcium and TRP channels in pulmonary vascular smooth muscle cell proliferation. News Physiol Sci 2004, 19:44-50.
109. Large W.A. Receptor-operated Ca2(+)-permeable nonselective cation channels in vascular smooth muscle: a physiologic perspective. J Cardiovasc Electrophysiol 2002, 13:493-501.
110. Le Cras T.D., Kim D.H., Markham N.E., Abman A.S. Early abnormalities of pulmonary vascular development in the Fawn-Hooded rat raised at Denver's altitude. Am J Physiol Lung Cell Mol Physiol 2000, 279:L283-291.
111. Ledoux J., Werner M.E., Brayden J.E., Nelson M.T. Calcium-activated potassium channels and the regulation of vascular tone. Physiology (Bethesda) 2006, 21:69-78.
112. Legrain S., Berr C., Frenoy N., Gourlet V., Debuire B., Baulieu E.E. Dehydroepiandrosterone sulfate in a long-term care aged population. Gerontology 1995, 41:343-351.
113. Levin D.L., Heymann M.A., Kitterman J.A., Gregory G.A., Phibbs R.H., Rudolph A.M. Persistent pulmonary hypertension of the newborn infant. J Pediatr 1976, 89:626-630.
114. Lin M.J., Leung G.P., Zhang W.M., Yang X.R., Yip K.P., Tse C.M., et al. Chronic hypoxia-induced upregulation of store-operated and receptor-operated Ca2+ channels in pulmonary arterial smooth muscle cells: a novel mechanism of hypoxic pulmonary hypertension. Circ Res 2004, 95:496-505.
115. Lin S.Y., Cui H., Yusta B., Belsham D.D. IGF-I signaling prevents dehydroepiandrosterone (DHEA)-induced apoptosis in hypothalamic neurons. Mol Cell Endocrinol 2004, 214:127-135.
116. Liu D., Dillon J.S. Dehydroepiandrosterone activates endothelial cell nitric-oxide synthase by a specific plasma membrane receptor coupled to Galpha(i2, 3). J Biol Chem 2002, 277:21379-21388.
117. Liu D., Dillon J.S. Dehydroepiandrosterone stimulates nitric oxide release in vascular endothelial cells: evidence for a cell surface receptor. Steroids 2004, 69:279-289.
118. Liu D., Si H., Reynolds K.A., Zhen W., Jia Z., Dillon J.S. Dehydroepiandrosterone protects vascular endothelial cells against apoptosis through a G{alpha}i-protein-dependent activation of phosphatidylinositol 3-kinase/Akt and regulation of anti-apoptotic Bcl-2 expression. Endocrinology 2007.
119. Loirand G., Guerin P., Pacaud P. Rho kinases in cardiovascular physiology and pathophysiology. Circ Res 2006, 98:322-334.
120. Long L., MacLean M.R., Jeffery T.K., Morecroft I., Yang X., Rudarakanchana N., et al. Serotonin increases susceptibility to pulmonary hypertension in BMPR2-deficient mice. Circ Res 2006, 98:818-827.
121. Mattocks A.R. Toxicity of pyrrolizidine alkaloids. Nature 1968, 217:723-728.
122. Mauban J.R., Remillard C.V., Yuan J.X. Hypoxic pulmonary vasoconstriction: role of ion channels. J Appl Physiol 2005, 98:415-420.
123. Mazat L., Lafont S., Berr C., Debuire B., Tessier J.F., Dartigues J.F., et al. Prospective measurements of dehydroepiandrosterone sulfate in a cohort of elderly subjects: relationship to gender, subjective health, smoking habits, and 10-year mortality. Proc Natl Acad Sci U S A 2001, 98:8145-8150.
124. McMurtry I.F., Davidson A.B., Reeves J.T., Grover R.F. Inhibition of hypoxic pulmonary vasoconstriction by calcium antagonists in isolated rat lungs. Circ Res 1976, 38:99-104.
125. McMurtry M.S., Moudgil R., Hashimoto K., Bonnet S., Michelakis E.D., Archer S.L. Overexpression of human bone morphogenetic protein receptor 2 does not ameliorate monocrotaline pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 2007, 292:L872-878.
126. Means A.R. Calcium, calmodulin and cell cycle regulation. FEBS Lett 1994, 347:1-4.
127. Meyrick B., Reid L. Development of pulmonary arterial changes in rats fed Crotalaria spectabilis. Am J Pathol 1979, 94:37-51.
128. Michelakis E.D. Spatio-temporal diversity of apoptosis within the vascular wall in pulmonary arterial hypertension: heterogeneous BMP signaling may have therapeutic implications. Circ Res 2006, 98:172-175.
129. Michelakis E.D., McMurtry M.S., Wu X.C., Dyck J.R., Moudgil R., Hopkins T.A., et al. Dichloroacetate, a metabolic modulator, prevents and reverses chronic hypoxic pulmonary hypertension in rats: role of increased expression and activity of voltage-gated potassium channels. Circulation 2002, 105:244-250.
130. Migeon C.J., Keller A.R., Lawrence B., Shepard T.H. Dehydroepiandrosterone and androsterone levels in human plasma: effect of age and sex; day-to-day and diurnal variations. J Clin Endocrinol Metab 1957, 17:1051-1062.
131. Miller W.L. Androgen biosynthesis from cholesterol to DHEA. Mol Cell Endocrinol 2002, 198:7-14.
132. Mitchell L.E., Sprecher D.L., Borecki I.B., Rice T., Laskarzewski P.M., Rao D.C. Evidence for an association between dehydroepiandrosterone sulfate and nonfatal, premature myocardial infarction in males. Circulation 1994, 89:89-93.
133. Mogami H., Kojima I. Stimulation of calcium entry is prerequisite for DNA synthesis induced by platelet-derived growth factor in vascular smooth muscle cells. Biochem Biophys Res Commun 1993, 196:650-658.
134. Mohan P.F., Benghuzzi H. Effect of dehydroepiandrosterone on endothelial cell proliferation. Biomed Sci Instrum 1997, 33:550-555.
135. Morales A.J., Nolan J.J., Nelson J.C., Yen S.S. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab 1994, 78:1360-1367.
136. Morecroft I., Dempsie Y., Bader M., Walther D.J., Kotnik K., Loughlin L., et al. Effect of tryptophan hydroxylase 1 deficiency on the development of hypoxia-induced pulmonary hypertension. Hypertension 2007, 49:232-236.
137. Morin F.C. Ligating the ductus arteriosus before birth causes persistent pulmonary hypertension in the newborn lamb. Pediatr Res 1989, 25:245-250.
138. Muraki S., Tohse N., Seki S., Nagashima M., Yamada Y., Abe T., et al. Decrease in the Ca2+-activated K+current of pulmonary arterial smooth muscle in pulmonary hypertension rats. Naunyn Schmiedebergs Arch Pharmacol 2001, 364:183-192.
139. Nagaoka T., Fagan K.A., Gebb S.A., Morris K.G., Suzuki T., Shimokawa H., et al. Inhaled Rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension. Am J Respir Crit Care Med 2005, 171:494-499.
140. Nagaoka T., Morio Y., Casanova N., Bauer N., Gebb S., McMurtry I., et al. Rho/Rho kinase signaling mediates increased basal pulmonary vascular tone in chronically hypoxic rats. Am J Physiol Lung Cell Mol Physiol 2004, 287:L665-672.
141. Nagaoka T., Muramatsu M., Sato K., McMurtry I., Oka M., Fukuchi Y. Mild hypoxia causes severe pulmonary hypertension in fawn-hooded but not in Tester Moriyama rats. Respir Physiol 2001, 127:53-60.
142. Nelson M.T., Patlak J.B., Worley J.F., Standen N.B. Calcium channels, potassium channels, and voltage dependence of arterial smooth muscle tone. Am J Physiol 1990, 259:C3-18.
143. Nelson M.T., Quayle J.M. Physiological roles and properties of potassium channels in arterial smooth muscle. Am J Physiol 1995, 268:C799-822.
144. Nephew K.P., Sheeler C.Q., Dudley M.D., Gordon S., Nayfield S.G., Khan S.A. Studies of dehydroepiandrosterone (DHEA) with the human estrogen receptor in yeast. Mol Cell Endocrinol 1998, 143:133-142.
145. Newcomer L.M., Manson J.E., Barbieri R.L., Hennekens C.H., Stampfer M.J. Dehydroepiandrosterone sulfate and the risk of myocardial infarction in US male physicians: a prospective study. Am J Epidemiol 1994, 140:870-875.
146. Nieschlag E., Loriaux D.L., Ruder H.J., Zucker I.R., Kirschner M.A., Lipsett M.B. The secretion of dehydroepiandrosterone and dehydroepiandrosterone sulphate in man. J Endocrinol 1973, 57:123-134.
147. Oka M., Fagan K.A., Jones P.L., McMurtry I.F. Therapeutic potential of RhoA/Rho kinase inhibitors in pulmonary hypertension. Br J Pharmacol 2008, 155:444-454.
148. Oka M., Karoor V., Homma N., Nagaoka T., Sakao E., Golembeski S.M., et al. Dehydroepiandrosterone upregulates soluble guanylate cyclase and inhibits hypoxic pulmonary hypertension. Cardiovasc Res 2007, 74:377-387.
149. Olschewski A., Li Y., Tang B., Hanze J., Eul B., Bohle R.M., et al. Impact of TASK-1 in human pulmonary artery smooth muscle cells. Circ Res 2006, 98:1072-1080.
150. Olschewski H., Simonneau G., Galie N., Higenbottam T., Naeije R., Rubin L.J., et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002, 347:322-329.
151. Orio P., Rojas P., Ferreira G., Latorre R. New disguises for an old channel: MaxiK channel beta-subunits. News Physiol Sci 2002, 17:156-161.
152. Pal S., Hartnett K.A., Nerbonne J.M., Levitan E.S., Aizenman E. Mediation of neuronal apoptosis by Kv2.1-encoded potassium channels. J Neurosci 2003, 23:4798-4802.
153. Pap M., Cooper G.M. Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-Kinase/Akt cell survival pathway. J Biol Chem 1998, 273:19929-19932.
154. Parekh A.B., Penner R. Store depletion and calcium influx. Physiol Rev 1997, 77:901-930.
155. Parker C.R. Dehydroepiandrosterone and dehydroepiandrosterone sulfate production in the human adrenal during development and aging. Steroids 1999, 64:640-647.
156. Pastorino J.G., Hoek J.B. Hexokinase II: the integration of energy metabolism and control of apoptosis. Curr Med Chem 2003, 10:1535-1551.
157. Pastorino J.G., Hoek J.B., Shulga N. Activation of glycogen synthase kinase 3beta disrupts the binding of hexokinase II to mitochondria by phosphorylating voltage-dependent anion channel and potentiates chemotherapy-induced cytotoxicity. Cancer Res 2005, 65:10545-10554.
158. Pastorino J.G., Shulga N., Hoek J.B. Mitochondrial binding of hexokinase II inhibits Bax-induced cytochrome c release and apoptosis. J Biol Chem 2002, 277:7610-7618.
159. Patel A.J., Honore E. Molecular physiology of oxygen-sensitive potassium channels. Eur Respir J 2001, 18:221-227.
160. Patel A.J., Lazdunski M., Honore E. Kv2.1/Kv9.3, a novel ATP-dependent delayed-rectifier K+channel in oxygen-sensitive pulmonary artery myocytes. Embo J 1997, 16:6615-6625.
161. Peng W., Hoidal J.R., Farrukh I.S. Role of a novel KCa opener in regulating K+channels of hypoxic human pulmonary vascular cells. Am J Respir Cell Mol Biol 1999, 20:737-745.
162. Peng W., Hoidal J.R., Karwande S.V., Farrukh I.S. Effect of chronic hypoxia on K+channels: regulation in human pulmonary vascular smooth muscle cells. Am J Physiol 1997, 272:C1271-1278.
163. Petkov V., Mosgoeller W., Ziesche R., Raderer M., Stiebellehner L., Vonbank K., et al. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest 2003, 111:1339-1346.
164. Platoshyn O., Golovina V.A., Bailey C.L., Limsuwan A., Krick S., Juhaszova M., et al. Sustained membrane depolarization and pulmonary artery smooth muscle cell proliferation. Am J Physiol Cell Physiol 2000, 279:C1540-1549.
165. Platoshyn O., Yu Y., Golovina V.A., McDaniel S.S., Krick S., Li L., et al. Chronic hypoxia decreases K(V) channel expression and function in pulmonary artery myocytes. Am J Physiol Lung Cell Mol Physiol 2001, 280:L801-812.
166. Pozeg Z.I., Michelakis E.D., McMurtry M.S., Thebaud B., Wu X.C., Dyck J.R., et al. In vivo gene transfer of the O2-sensitive potassium channel Kv1.5 reduces pulmonary hypertension and restores hypoxic pulmonary vasoconstriction in chronically hypoxic rats. Circulation 2003, 107:2037-2044.
167. Priest R.M., Robertson T.P., Leach R.M., Ward J.P. Membrane potential-dependent and -independent vasodilation in small pulmonary arteries from chronically hypoxic rats. J Pharmacol Exp Ther 1998, 285:975-982.
168. Rabinovitch M. Elastase and the pathobiology of unexplained pulmonary hypertension. Chest 1998, 114:213S-224S.
169. Rabinovitch M., Fisher K., Gamble W., Reid L., Treves S. Thallium-201: quantitation of right ventricular hypertrophy in chronically hypoxic rats. Radiology 1979, 130:223-225.
170. Rabkin J.G., McElhiney M.C., Rabkin R., McGrath P.J., Ferrando S.J. Placebo-controlled trial of dehydroepiandrosterone (DHEA) for treatment of nonmajor depression in patients with HIV/AIDS. Am J Psychiatry 2006, 163:59-66.
171. Raffestin B., Adnot S., Mercadier J.J., Levame M., Duc P., Braquet P., et al. Synthesis and secretion of atrial natriuretic factor during chronic hypoxia: a study in the conscious instrumented rat. Clin Sci (Lond) 1990, 78:597-603.
172. Rainio E.M., Sandholm J., Koskinen P.J. Cutting edge: transcriptional activity of NFATc1 is enhanced by the Pim-1 kinase. J Immunol 2002, 168:1524-1527.
173. Ratz P.H., Berg K.M., Urban N.H., Miner A.S. Regulation of smooth muscle calcium sensitivity: KCl as a calcium-sensitizing stimulus. Am J Physiol Cell Physiol 2005, 288:C769-783.
174. Reddy V.M., Meyrick B., Wong J., Khoor A., Liddicoat J.R., Hanley F.L., et al. In utero placement of aortopulmonary shunts. A model of postnatal pulmonary hypertension with increased pulmonary blood flow in lambs. Circulation 1995, 92:606-613.
175. Reeve H.L., Michelakis E., Nelson D.P., Weir E.K., Archer S.L. Alterations in a redox oxygen sensing mechanism in chronic hypoxia. J Appl Physiol 2001, 90:2249-2256.
176. Reid M.J., Lame M.W., Morin D., Wilson D.W., Segall H.J. Involvement of cytochrome P450 3A in the metabolism and covalent binding of 14C-monocrotaline in rat liver microsomes. J Biochem Mol Toxicol 1998, 12:157-166.
177. Remillard C.V., Yuan J.X. Activation of K+channels: an essential pathway in programmed cell death. Am J Physiol Lung Cell Mol Physiol 2004, 286:L49-67.
178. Rich S., Brundage B.H. High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy. Circulation 1987, 76:135-141.
179. Rich S., Kaufmann E., Levy P.S. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992, 327:76-81.
180. Rubin L.J., Badesch D.B., Barst R.J., Galie N., Black C.M., Keogh A., et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002, 346:896-903.
181. Salvaterra C.G., Goldman W.F. Acute hypoxia increases cytosolic calcium in cultured pulmonary arterial myocytes. Am J Physiol 1993, 264:L323-328.
182. Salvini S., Stampfer M.J., Barbieri R.L., Hennekens C.H. Effects of age, smoking and vitamins on plasma DHEAS levels: a cross-sectional study in men. J Clin Endocrinol Metab 1992, 74:139-143.
183. Sato K., Webb S., Tucker A., Rabinovitch M., O'Brien R.F., McMurtry I.F., et al. Factors influencing the idiopathic development of pulmonary hypertension in the fawn hooded rat. Am Rev Respir Dis 1992, 145:793-797.
184. Savineau J.P., Marthan R. Modulation of the calcium sensitivity of the smooth muscle contractile apparatus: molecular mechanisms, pharmacological and pathophysiological implications. Fundam Clin Pharmacol 1997, 11:289-299.
185. Schermuly R.T., Dony E., Ghofrani H.A., Pullamsetti S., Savai R., Roth M., et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005, 115:2811-2821.
186. Schriock E.D., Buffington C.K., Hubert G.D., Kurtz B.R., Kitabchi A.E., Buster J.E., et al. Divergent correlations of circulating dehydroepiandrosterone sulfate and testosterone with insulin levels and insulin receptor binding. J Clin Endocrinol Metab 1988, 66:1329-1331.
187. Schwartz A.G., Pashko L., Whitcomb J.M. Inhibition of tumor development by dehydroepiandrosterone and related steroids. Toxicol Pathol 1986, 14:357-362.
188. Semenza G.L. Involvement of hypoxia-inducible factor 1 in pulmonary pathophysiology. Chest 2005, 128:592S-594S.
189. Shen T., Cseresnyes Z., Liu Y., Randall W.R., Schneider M.F. Regulation of the nuclear export of the transcription factor NFATc1 by protein kinases after slow fibre type electrical stimulation of adult mouse skeletal muscle fibres. J Physiol 2007, 579:535-551.
190. Shimoda L.A., Sham J.S., Shimoda T.H., Sylvester J.T. L-type Ca(2+) channels, resting [Ca(2+)](i), and ET-1-induced responses in chronically hypoxic pulmonary myocytes. Am J Physiol Lung Cell Mol Physiol 2000, 279:L884-894.
191. Shimoda L.A., Sylvester J.T., Sham J.S. Mobilization of intracellular Ca(2+) by endothelin-1 in rat intrapulmonary arterial smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2000, 278:L157-164.
192. Short A.D., Bian J., Ghosh T.K., Waldron R.T., Rybak S.L., Gill D.L. Intracellular Ca2+ pool content is linked to control of cell growth. Proc Natl Acad Sci U S A 1993, 90:4986-4990.
193. Simoncini T., Mannella P., Fornari L., Varone G., Caruso A., Genazzani A.R. Dehydroepiandrosterone modulates endothelial nitric oxide synthesis via direct genomic and nongenomic mechanisms. Endocrinology 2003, 144:3449-3455.
194. Simonneau G., Barst R.J., Galie N., Naeije R., Rich S., Bourge R.C., et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002, 165:800-804.
195. Simonneau G., Galie N., Rubin L.J., Langleben D., Seeger W., Domenighetti G., et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004, 43:5S-12S.
196. Simonneau G., Robbins I.M., Beghetti M., Channick R.N., Delcroix M., Denton C.P., et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009, 54:S43-54.
197. Sitbon O., Humbert M., Jais X., Ioos V., Hamid A.M., Provencher S., et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005, 111:3105-3111.
198. Slowinska-Srzednicka J., Zgliczynski S., Ciswicka-Sznajderman M., Srzednicki M., Soszynski P., Biernacka M., et al. Decreased plasma dehydroepiandrosterone sulfate and dihydrotestosterone concentrations in young men after myocardial infarction. Atherosclerosis 1989, 79:197-203.
199. Smirnov S.V., Robertson T.P., Ward J.P., Aaronson P.I. Chronic hypoxia is associated with reduced delayed rectifier K+current in rat pulmonary artery muscle cells. Am J Physiol 1994, 266:H365-370.
200. Somlyo A.P., Somlyo A.V. Signal transduction and regulation in smooth muscle. Nature 1994, 372:231-236.
201. Somlyo A.P., Somlyo A.V. Ca2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase. Physiol Rev 2003, 83:1325-1358.
202. Steiner M.K., Preston I.R., Klinger J.R., Hill N.S. Pulmonary hypertension: inhaled nitric oxide, sildenafil and natriuretic peptides. Curr Opin Pharmacol 2005, 5:245-250.
203. Stenmark K.R., Meyrick B., Galie N., Mooi W.J., McMurtry I.F. Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol 2009, 297:L1013-1032.
204. Sugita T., Hyers T.M., Dauber I.M., Wagner W.W., McMurtry I.F., Reeves J.T. Lung vessel leak precedes right ventricular hypertrophy in monocrotaline-treated rats. J Appl Physiol 1983, 54:371-374.
205. Sulcova J., Hill M., Masek Z., Ceska R., Novacek A., Hampl R., et al. Effects of transdermal application of 7-oxo-DHEA on the levels of steroid hormones, gonadotropins and lipids in healthy men. Physiol Res 2001, 50:9-18.
206. Tilvis R.S., Kahonen M., Harkonen M. Dehydroepiandrosterone sulfate, diseases and mortality in a general aged population. Aging (Milano) 1999, 11:30-34.
207. Toro L., Vaca L., Stefani E. Calcium-activated potassium channels from coronary smooth muscle reconstituted in lipid bilayers. Am J Physiol 1991, 260:H1779-1789.
208. Treins C., Giorgetti-Peraldi S., Murdaca J., Semenza G.L., Van Obberghen E. Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway. J Biol Chem 2002, 277:27975-27981.
209. Trivedi D.P., Khaw K.T. Dehydroepiandrosterone sulfate and mortality in elderly men and women. J Clin Endocrinol Metab 2001, 86:4171-4177.
210. Uehata M., Ishizaki T., Satoh H., Ono T., Kawahara T., Morishita T., et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 1997, 389:990-994.
211. Wang H., Zhang Y., Cao L., Han H., Wang J., Yang B., et al. HERG K+channel, a regulator of tumor cell apoptosis and proliferation. Cancer Res 2002, 62:4843-4848.
212. Wang J., Juhaszova M., Rubin L.J., Yuan X.J. Hypoxia inhibits gene expression of voltage-gated K+channel alpha subunits in pulmonary artery smooth muscle cells. J Clin Invest 1997, 100:2347-2353.
213. Wang J., Weigand L., Lu W., Sylvester J.T., Semenza G.L., Shimoda L.A. Hypoxia inducible factor 1 mediates hypoxia-induced TRPC expression and elevated intracellular Ca2+ in pulmonary arterial smooth muscle cells. Circ Res 2006, 98:1528-1537.
214. Wang X.X., Zhang F.R., Shang Y.P., Zhu J.H., Xie X.D., Tao Q.M., et al. Transplantation of autologous endothelial progenitor cells may be beneficial in patients with idiopathic pulmonary arterial hypertension: a pilot randomized controlled trial. J Am Coll Cardiol 2007, 49:1566-1571.
215. Wanstall J.C., Gambino A., Jeffery T.K., Cahill M.M., Bellomo D., Hayward N.K., et al. Vascular endothelial growth factor-B-deficient mice show impaired development of hypoxic pulmonary hypertension. Cardiovasc Res 2002, 55:361-368.
216. Webb S.J., Geoghegan T.E., Prough R.A., Michael Miller K.K. The biological actions of dehydroepiandrosterone involves multiple receptors. Drug Metab Rev 2006, 38:89-116.
217. Werchan P.M., Summer W.R., Gerdes A.M., McDonough K.H. Right ventricular performance after monocrotaline-induced pulmonary hypertension. Am J Physiol 1989, 256:H1328-1336.
218. Wharton J., Strange J.W., Moller G.M., Growcott E.J., Ren X., Franklyn A.P., et al. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med 2005, 172:105-113.
219. Williams M.R., Dawood T., Ling S., Dai A., Lew R., Myles K., Funder J.W., Sudhir K., Komesaroff P.A. Dehydroepiandrosterone increases endothelial cell proliferation in vitro and improves endothelial function in vivo by mechanisms independent of androgen and estrogen receptors. J Clin Endocrinol Metab 2004, 89:4708-4715.
220. Williams M.R., Ling S., Dawood T., Hashimura K., Dai A., Li H., et al. Dehydroepiandrosterone inhibits human vascular smooth muscle cell proliferation independent of ARs and ERs. J Clin Endocrinol Metab 2002, 87:176-181.
221. Wu F.C., von Eckardstein A. Androgens and coronary artery disease. Endocr Rev 2003, 24:183-217.
222. Yu S.P., Choi D.W. Ions, cell volume, and apoptosis. Proc Natl Acad Sci U S A 2000, 97:9360-9362.
223. Yu S.P., Yeh C.H., Sensi S.L., Gwag B.J., Canzoniero L.M., Farhangrazi Z.S., et al. Mediation of neuronal apoptosis by enhancement of outward potassium current. Science 1997, 278:114-117.
224. Yu Y., Fantozzi I., Remillard C.V., Landsberg J.W., Kunichika N., Platoshyn O., et al. Enhanced expression of transient receptor potential channels in idiopathic pulmonary arterial hypertension. Proc Natl Acad Sci U S A 2004, 101:13861-13866.
225. Yuan J.X., Aldinger A.M., Juhaszova M., Wang J., Conte J.V., Gaine S.P., et al. Dysfunctional voltage-gated K+channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. Circulation 1998, 98:1400-1406.
226. Yuan X.J. Voltage-gated K+currents regulate resting membrane potential and [Ca2+]i in pulmonary arterial myocytes. Circ Res 1995, 77:370-378.
227. Zamzami N., Kroemer G. The mitochondrion in apoptosis: how Pandora's box opens. Nat Rev Mol Cell Biol 2001, 2:67-71.
228. Zhang S., Fantozzi I., Tigno D.D., Yi E.S., Platoshyn O., Thistlethwaite P.A., et al. Bone morphogenetic proteins induce apoptosis in human pulmonary vascular smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2003, 285:L740-754.
229. Zhao L., Mason N.A., Morrell N.W., Kojonazarov B., Sadykov A., Maripov A., et al. Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation 2001, 104:424-428.
230. Zumoff B., Troxler R.G., O'Connor J., Rosenfeld R.S., Kream J., Levin J., et al. Abnormal hormone levels in men with coronary artery disease. Arteriosclerosis 1982, 2:58-67.